Please Wait.....
Report
Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 91 Pages I DelveInsight
DelveInsight's 'Generalized Myasthenia Gravis (gMG)- Epidemiology Forecast-2032' report delivers an in-depth understanding of Generalized Myasthenia Gravis (gMG) historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Generalized Myasthenia Gravis (gMG) Disease Understanding
Myasthenia gravis (MG) is an autoimmune disease that occurs when the immune system attacks the body's own tissues. In MG, that attack interrupts the connection between nerve and muscle-the neuromuscular junction. MG is characterized mostly by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab).
Generalized Myasthenia Gravis (gMG) Epidemiology
The Generalized Myasthenia Gravis (gMG) epidemiology division provides insights about the historical and prevalent patient pool, along with the forecasted trend for all the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.
Key Findings
The total diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG) patients in the 7MM are increasing during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Generalized Myasthenia Gravis (gMG) epidemiology segmented as the total diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG), gender-specific cases of Generalized Myasthenia Gravis (gMG), and antibodies-specific cases of Generalized Myasthenia Gravis (gMG). The report includes the diagnosed prevalent cases scenario of Generalized Myasthenia Gravis (gMG) in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country-wise Generalized Myasthenia Gravis (gMG) Epidemiology
The epidemiology segment also provides the Generalized Myasthenia Gravis (gMG) epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG) associated in the 7MM countries were approximately 116,100 in 2021.
- As per the estimates, the United States has the largest diagnosed prevalent population of Generalized Myasthenia Gravis (gMG)
- Among the EU5 countries, Germany had the highest diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG), followed by the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent cases with around 8,800 cases in 2021.
Scope of the Report
- The Generalized Myasthenia Gravis (gMG) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
- The Generalized Myasthenia Gravis (gMG) Epidemiology Report and Model provide an overview of Generalized Myasthenia Gravis (gMG)' risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides insight into Generalized Myasthenia Gravis (gMG)' historical and forecasted patient pool in the seven major markets covering the United States, the EU-5 (Germany, Spain, France, Italy, UK), and Japan.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis (gMG).
- The report provides the segmentation of the Generalized Myasthenia Gravis (gMG) epidemiology by the Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
- The report provides the Generalized Myasthenia Gravis (gMG) epidemiology segmentation by gender-specific cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
- The report provides the Generalized Myasthenia Gravis (gMG) epidemiology segmentation by antibodies-specific cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
Report Highlights
- 11-year Forecast of Generalized Myasthenia Gravis (gMG) epidemiology
- 7MM Coverage
- Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG)
- Gender-specific cases of Generalized Myasthenia Gravis (gMG)
- Antibodies-specific Cases of Generalized Myasthenia Gravis (gMG)
KOL Views
We interview KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What are the major factors that will drive the change in the patient population in Generalized Myasthenia Gravis (gMG) during the forecast period (2019-2032)?
- What are the key findings of the Generalized Myasthenia Gravis (gMG) epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of Generalized Myasthenia Gravis (gMG) patients across the 7MM during the forecast period (2019-2032)?
- Among the EU-5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2019-2032)?
- What are the disease risks, burden, and unmet needs of Generalized Myasthenia Gravis (gMG) market?
- What are the current treatment patterns for Generalized Myasthenia Gravis (gMG)?
Reasons to buy
The Generalized Myasthenia Gravis (gMG) epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Generalized Myasthenia Gravis (gMG) market.
- Quantify patient populations in the global Generalized Myasthenia Gravis (gMG) market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the gender that present the best opportunities for Generalized Myasthenia Gravis (gMG) therapeutics in each market covered.
- Understand the magnitude of the Generalized Myasthenia Gravis (gMG) population by its diagnosed prevalence.
- Understand the magnitude of the Generalized Myasthenia Gravis (gMG) population by its Gender-specific cases.
- Understand the magnitude of the Generalized Myasthenia Gravis (gMG) population by its Antibodies-specific cases.
- The Generalized Myasthenia Gravis (gMG) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The Generalized Myasthenia Gravis (gMG) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. Generalized Myasthenia Gravis (gMG) Market Overview at a Glance
3.1. Patient Share (%) Distribution of Generalized Myasthenia Gravis (gMG) in 2019
3.2. Patient Share (%) Distribution of Generalized Myasthenia Gravis (gMG) in 2032
4. Executive Summary of Myasthenia Gravis (MG)
5. Disease Background and Overview
5.1. Introduction
5.2. Types of MG
5.3. Clinical Classification of MG
5.4. Etiology
5.5. Risk Factors
5.6. Clinical Manifestations
5.7. Pathophysiology
5.8. Biomarkers
5.9. Diagnosis
5.9.1. Diagnostic guidelines
5.10. Differential Diagnosis
5.11. Treatment Guidelines
5.11.1. International consensus guidance for management of myasthenia gravis
5.11.2. Italian recommendations to treat myasthenia gravis
5.11.3. German Neurological Society Guidelines for myasthenia gravis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Diagnosed Prevalent Population of Generalized Myasthenia Gravis (gMG)
6.3. Assumptions and Rationale
6.3.1. Assumptions and Rationale
6.4. The United States
6.4.1. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the United States
6.4.2. Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in the United States
6.4.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in the United States
6.5. EU-5
6.5.1. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in EU-5
6.5.2. Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in the EU-5
6.5.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in EU-5
6.6. Japan
6.6.1. Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in Japan
6.6.2. Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in Japan
6.6.3. Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in Japan
7. Patient Journey
8. KOL Views
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Table 1: Summary of Generalized Myasthenia Gravis (gMG), Market, Epidemiology, and Key Events (2019-2032)
Table 2: Classification of MG subgroups
Table 3: Proposed Diagnostic Criteria for Myasthenia Gravis - Japanese Treatment Guidelines
Table 4: Treatment options for MG German Neurological Society Guidelines
Table 5: 7MM Total Diagnosed Prevalent Population of Generalized Myasthenia Gravis (gMG) (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the US (2019-2032)
Table 7: Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in the US (2019-2032)
Table 8: Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in the US (2019-2032)
Table 9: Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in EU-5 (2019-2032)
Table 10: Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in EU-5 (2019-2032)
Table 11: Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in EU-5 (2019-2032)
Table 12: Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in Japan (2019-2032)
Table 13: Gender-Specific Cases of Generalized Myasthenia Gravis (gMG) in Japan (2019-2032)
Table 14: Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in Japan (2019-2032)
Figure 1: Types of MG
Figure 2: Risk Factors of MG
Figure 3: Speculative mechanisms of AChR MG immunopathology
Figure 4: Speculative mechanisms of MuSK MG immunopathology
Figure 5: Diagnostic algorithm for Myasthenia Gravis (MG)
Figure 6: 7MM Total Diagnosed Prevalent Population of Generalized Myasthenia Gravis (gMG) (2019-2032)
Figure 7: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the US (2019-2032)
Figure 8: Gender-specific cases of Generalized Myasthenia Gravis (gMG) in the US (2019-2032)
Figure 9: Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in the US (2019-2032)
Figure 10: Total Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in EU-5 (2019-2032)
Figure 11: Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in EU-5 (2019-2032)
Figure 12: Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in EU-5 (2019-2032)
Figure 13: Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in Japan (2019-2032)
Figure 14: Gender-specific Cases of Generalized Myasthenia Gravis (gMG) in Japan (2019-2032)
Figure 15: Autoantibodies-specific Cases of Generalized Myasthenia Gravis (gMG) in Japan (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security